Key result
Angiotensin II promotes endometrial cancer cell survival by boosting proliferation and reducing apoptosis.
Why the study?
Uncontrolled proliferation stimulated by local factors such as angiotensin is a key process in endometrial cancer development, but the influence of angiotensin II on human EC cells needed evaluation.
Does Angiotensin II promote survival and malignant transformation in human endometrial cancer cells?
Does Angiotensin II promote survival and malignant transformation in human endometrial cancer cells?
Angiotensin II promotes proliferation, survival, and epithelial-mesenchymal transition in endometrial cancer cells, suggesting a role in early and late stages of malignant transformation.
These preclinical effects are hypothesis-generating; should not influence RAS inhibitor use in endometrial cancer patients.
Endometrial cancer (EC) is one of the most common female cancers. One of the key processes involved in EC development is uncontrolled proliferation stimulated by local factors such as angiotensin. The aim of the present study was to evaluate the influence of angiotensin II (Ang II) on human EC cells. Biological assays and gene expression analysis were performed on three cell lines: ISH, MFE-296 and MFE-280. Our results indicated that at the beginning of cancerogenesis Ang II induced abnormal proliferation at lower doses. We also showed that dose-dependent induction of proliferation was connected with changes in the expression of MKI67, CCND1 and CCNE1 genes in well- and poorly differentiated cancer cells. After Ang II treatment, poorly differentiated endometrial cancer cell line acquired a mesenchymal phenotype, which was characterized by induced expression of EMT-related genes (VIM, CD44, SNAI1, ZEB1 and ZEB2). Our study revealed that Ang II influences EC cells in terms of cancer-related processes, and is responsible for increased proliferation, reduction in apoptosis, increased mobility and modulation of adhesion potential. Its effect and effectiveness appear to be highly connected with the differentiation status of the cancerous cells, as Ang II appears to play a crucial role in the early and late stages of malignant transformation.
No takes yet. Share an insight, caveat, or question.
Nowakowska et al. (2016) studied Endometrial cancer (in vitro). Angiotensin II vs. Control medium without Angiotensin II was evaluated on Cell proliferation, apoptosis, and mobility. Angiotensin II promoted endometrial cancer cell survival by increasing proliferation, reducing apoptosis, and modulating cell mobility and adhesion in a dose-dependent manner.